Mechanistic studies of the genetic contribution of desmoplakin to pulmonary fibrosis in alveolar type 2 cells

桥粒斑蛋白对肺泡2型细胞肺纤维化的遗传贡献机制研究

基本信息

  • 批准号:
    10736228
  • 负责人:
  • 金额:
    $ 79.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-15 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract In recent decades, genome-wide association studies (GWAS) have identified genetic variants associated with a variety of traits and diseases, a critical first step towards understanding the molecular mechanisms that underlie common health conditions. In many cases, however, the functions of GWAS genes, the mechanisms and consequences of their dysfunction, or the relevant cell types in which their dysfunction manifests a clinically significant phenotype remain poorly understood. The GWAS gene DSP encodes a junctional protein found in desmosomes that provide structural integrity to epithelial cells in tissues that experience mechanical stress, such as skin, heart, and lung. A variant associated with DSP expression in lung but not other tissues, rs2076295, has been linked to both pulmonary fibrosis and chronic obstructive pulmonary disease susceptibility in GWAS. In recent years, we and others have developed protocols to differentiate, mature, and model disease in human AT2s derived from iPSCs (iAT2s) and in preparation for this proposal we have adapted this model system to interrogate lung disease-relevant GWAS discoveries. We hypothesize that reductions in DSP mediated through rs2076295 destabilize desmosomes to regulate AT2 phenotypes through modulation of Wnt/Tcf signaling either at homeostasis or in the setting of injury that impairs AT2 differentiation capacity and induces a profibrotic mesenchymal phenotype. To test this hypothesis in this proposal, we will test the mechanisms through which DSP regulates iAT2 maturation through CRISPR-based knockdown or overexpression of DSP or its binding partners. We will identify the contribution of reduced DSP expression on iAT2 transdifferentiation capacity and potential emergence of cells in a transitional state. We will then test the contribution of DSP to AT2 regenerative capacity and associated fibrotic lung injury in vivo using AT2-specific Dsp deletions in mice in combination with bleomycin injury. Finally, we will leverage LTRC data to determine mechanisms through which rs2076295 regulates gene expression and then validate those predictions in patient iAT2s.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW A WILSON其他文献

ANDREW A WILSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW A WILSON', 18)}}的其他基金

Personalized therapy for AATD-associated liver disease via IPS modeling
通过 IPS 建模对 AATD 相关肝病进行个性化治疗
  • 批准号:
    8888673
  • 财政年份:
    2015
  • 资助金额:
    $ 79.94万
  • 项目类别:
Personalized therapy for AATD-associated liver disease via IPS modeling
通过 IPS 建模对 AATD 相关肝病进行个性化治疗
  • 批准号:
    9518860
  • 财政年份:
    2015
  • 资助金额:
    $ 79.94万
  • 项目类别:
Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity
通过调节巨噬细胞 NFKB 和抗蛋白酶活性减轻肺气肿
  • 批准号:
    8294978
  • 财政年份:
    2010
  • 资助金额:
    $ 79.94万
  • 项目类别:
Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity
通过调节巨噬细胞 NFKB 和抗蛋白酶活性减轻肺气肿
  • 批准号:
    7953372
  • 财政年份:
    2010
  • 资助金额:
    $ 79.94万
  • 项目类别:
Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity
通过调节巨噬细胞 NFKB 和抗蛋白酶活性减轻肺气肿
  • 批准号:
    8117725
  • 财政年份:
    2010
  • 资助金额:
    $ 79.94万
  • 项目类别:
Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity
通过调节巨噬细胞 NFKB 和抗蛋白酶活性减轻肺气肿
  • 批准号:
    8501652
  • 财政年份:
    2010
  • 资助金额:
    $ 79.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了